Apeloa Pharmaceutical Co., Ltd.Founded in 1989, is a listed company on the main board of the Shenzhen
Stock Exchange (SZSE: 000739) and the pharmaceutical industry development
platform for Hengdian Group which is a well-known private enterprise in China.
The company ranks among the top 40 pharmaceutical companies in China, the 25th
in the "Top 100 Industrial Enterprises" (the second in Zhejiang), the
second in the "API Export" (the first in Zhejiang), and the top 5
CDMO companies in Yaozhi.com. Apeloa was also elected to The 14th "Top 100 Most Valuable Listed
Companies on the Main Board of China" and the second batch of Zhejiang
"Eagle Action" Cultivation Enterprises. In recent years, it has successively won the
honorary titles of Dongyang City's "Industrial Contribution Award"
and "Top Ten Taxpayers" in
Dongyang and Jinhua.
After more than 30 years of
development, Apeloa has established good pharmaceutical R&D and
manufacturing capabilities, forming three main business sectors of API, CDMO,
and Finished Dosage Form (FDF). The company has set up API technology center,
CDMO R&D center, and pharmaceutical research institute in Hengdian
headquarter, Shanghai, Boston, and Hangzhou respectively; Commercial production
facilities have been well in place in Dongyang Zhejiang, Weifang Shandong,
Dongzhi Anhui, and Quzhou Zhejiang.
Apeloa has accumulated a large number of technical achievements and talent
resources in its API business sector, and has taken the lead in China's API
industry and continues to tremendous invest in environmental protection,
technological improvement, and product R&D. With a strong competitive
advantage in terms of cost, quality, EHS and technology, Apeloa has become a
leading domestic company in special APIs .
As the major service provider
of CDMO business in the global innovative drug industry chain, Apeloa has built
a long-term strategic cooperative relationship with top domestic and foreign
big pharma and biotech companies, and has accumulated solid business and
maintained a rapid growth trend.
The FDF business adheres to the
strategy of differentiation and globalization to achieve rapid development. Eight products in FDF division have passed the new four-category approval
or drug consistency evaluation by NMPA, and a group of well-known domestic
brands such as "Baishixin" and "Tianliwei" have been
established. Apeloa has created competitive
advantages in the internal integration of API/FDF and superiority in high-tech barriers. The first
high-end controlled-release generic drug has been recently launched in US
market.
In line with international
standards, the company has secured a high-standard quality management system
and EHS management system to escort the healthy development of the company. The company actively fulfills its social responsibilities, and takes the
lead in the "three wastes" governance in the industry; actively
participates in social welfare activities such as paired poverty alleviation, disaster
rescue, and anti-epidemic donations, which have been widely praised by the
society.
The company insists on
high-quality development driven with scientific and technological innovation
and continues to increase investment in R&D activities. Surrounding the
three major business sectors, Apeloa has built an R&D innovation system
with a team of over 870 scientists currently. It has also jointly constructed
a variety of innovation platforms with academic institutes and has exhibited
certain advantages in subdivisions such as chiral resolution, flow chemistry,
bio-catalysis, and controlled release formulation technology. At the same time,
the company embraces intelligent manufacturing and promotes the construction of
" continuous, automatic, informationized and
intelligent" capabilities on the manufacturing side.
Apeloa upholds the core values of
"Mutual Creation, Mutual Wealth" and the core culture of " Compassion, Moderation, Teamwork and Action", fulfills the mission of
"Technology for Health", and implements the development strategy of
"Refine API, Strengthen CDMO, and Optimize FDF". The company actively
spreads the corporate culture of "happy learning, happy sports, happy
work".
To the future, Apeloa are
making great strides towards the realization of the high-quality development of
the enterprise and the grand vision of " To be a leading technology-based pharmaceutical manufacturing company in China ".